AR070043A1 - Derivados de triazol oxadiazoles; una composicion farmaceutica en base al compuesto; uso de los compuestos para preparar medicamentos y proceso de preparacion de dichos compuestos - Google Patents
Derivados de triazol oxadiazoles; una composicion farmaceutica en base al compuesto; uso de los compuestos para preparar medicamentos y proceso de preparacion de dichos compuestosInfo
- Publication number
- AR070043A1 AR070043A1 ARP080105591A ARP080105591A AR070043A1 AR 070043 A1 AR070043 A1 AR 070043A1 AR P080105591 A ARP080105591 A AR P080105591A AR P080105591 A ARP080105591 A AR P080105591A AR 070043 A1 AR070043 A1 AR 070043A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het
- hal
- denotes
- rest
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Los compuestos son utiles, en el tratamiento de trastornos autoinmunes, la esclerosis multiple. Reivindicacion 1: Un compuesto de acuerdo con la formula 1 en donde X es O o S; R1 denota H, Hal, CF3, OCF3, CN, o NO2; R2 es H, A o Hal; Ra es H, A, Ar, o Het; con la condicion que Ra no sea un grupo benzo[1,3]dioxolilo, o un grupo fenol que es no sustituido o sustituido por al menos un metilo, F, Cl, OMe, y/o OEt, si Rb es un grupo metilo; Rb es A, Ar, Het, OA, NHA, o NA2, Ar-alquilo, o Het-alquilo; Hal es F, Cl, Br o I; A es un alquilo ramificado o lineal C1-12, en donde uno o más, con preferencia 1 a 7 átomos de H pueden estar reemplazados por Hal, OR3, CN, CO2R3, cicloalquilo que posee 3 a 7 átomos de carbono de anillo, o N(R3)2 y en donde uno o más, preferentemente 1 a 7 grupos CH2 no adyacentes pueden estar reemplazados por O, NR3 o S y/o por grupos -CO-, -NR3CO-, -CONR3-, NR3CO2-, -NR3CONR3-, -CH=CH-, -C:::C-, o como en el resto de formula (2), o denota cicloalquilo o cicloalquilalquileno que posee 3-7 átomos de C de anillo; q es 1, 2, 3, o 4; Ar denota un anillo monocíclico o bicíclico, insaturado o aromático carbocíclico que posee 6 a 14 átomos de carbono que pueden estar no sustituidos o monosustituidos, disustituidos o trisustituidos por un sustituyente seleccionado de R4 y/o R5; Ar-alquilo denota un grupo arilo vinculado al resto de la molécula a través de una cadena alquileno C1-12, con preferencia una cadena alquileno C1-6. El Ar-alquilo preferido se encuentra unido al resto de la molécula a través de un grupo metileno o etileno. Het denota un anillo monocíclico o bicíclico, saturado, insaturado o aromático heterocíclico que posee 1 a 4 átomos de N, O y/o S que pueden estar no sustituidos o monosustituidos, disustituidos o trisustituidos por un sustituyente seleccionado de R4 y/o R5; y en donde uno o más grupos CH2 pueden estar reemplazados por -CO-; Het-alquilo denota un grupo Het unido al resto de la molécula a través de una cadena alquileno C1-12, preferentemente una cadena alquileno C1-6. El Het-alquilo preferido se encuentra unido al resto de la molécula a través de un grupo metileno o etileno; R4 y R5 se selecciona, cada uno, en forma independiente, de A, Hal, hidroxi, alcoxi, carboxi, carboxi-alquilo, perfluoralquilo, perfluor-alcoxi, acilo, alquilsulfonilo, sulfonilo, -SO2(R3)2, ciano, nitro, amino, amido, alquilo opcionalmente sustituido por un carboxi, -N(R3)2, -CO(NR3)2, -OR3, (NR3)COR3, -CO2R3, -COR3, o Ar-alquilo o Het-alquilo ambos opcionalmente sustituidos por A, Hal, un acilo, alquilsulfonilo, carboxi, -N(R3)2, -CON(R3)2, -OR3, (NR3)COR3, -CO2R3, -COR3, -SO2N(R3)2, o -SO2alquilo, NR3SO2alquilo, NR3SO2alquilo, resto de formula (3), o alquilo C1-6; R3 es H o A; y sus derivados, solvatos, tautomeros, sales y estereoisomeros farmacéuticamente aceptables, incluidas sus mezclas en todas las relaciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07150311 | 2007-12-21 | ||
| US6638508P | 2008-02-20 | 2008-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070043A1 true AR070043A1 (es) | 2010-03-10 |
Family
ID=39367513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105591A AR070043A1 (es) | 2007-12-21 | 2008-12-19 | Derivados de triazol oxadiazoles; una composicion farmaceutica en base al compuesto; uso de los compuestos para preparar medicamentos y proceso de preparacion de dichos compuestos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8202856B2 (es) |
| EP (1) | EP2250165B1 (es) |
| JP (1) | JP5451633B2 (es) |
| KR (1) | KR20100110834A (es) |
| CN (1) | CN101918395B (es) |
| AR (1) | AR070043A1 (es) |
| AU (1) | AU2008340113B2 (es) |
| BR (1) | BRPI0821357A2 (es) |
| CA (1) | CA2710345C (es) |
| EA (1) | EA020887B1 (es) |
| IL (1) | IL206514A (es) |
| MX (1) | MX2010007026A (es) |
| WO (1) | WO2009080663A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200924774A (en) * | 2007-10-26 | 2009-06-16 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5 |
| WO2009054794A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amino 1,2,4-triazole derivatives as modulators of mglur5 |
| US8389509B2 (en) * | 2009-01-23 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted pyrazole compounds |
| US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2014127149A1 (en) * | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Substituted 4,5-dihydropyrazole-1,2,4-oxadiazole derivatives as sphingosine receptor modulators |
| US20140235588A1 (en) * | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Substituted 1h-pyrazol-1,2,4-oxadiazole derivatives as sphingosine receptor modulators |
| WO2015126912A1 (en) * | 2014-02-18 | 2015-08-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Marinopyrrole derivatives and methods of making and using same |
| EP3265088A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance |
| WO2016141258A1 (en) * | 2015-03-04 | 2016-09-09 | Medivation Technologies, Inc. | Sterol regulatory element-binding proteins (srebps) inhibitors |
| TW202334101A (zh) * | 2017-04-06 | 2023-09-01 | 美商富曼西公司 | 殺真菌之噁二唑 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003062248A2 (en) * | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| WO2003062252A1 (en) * | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
| HUE055434T2 (hu) * | 2003-04-11 | 2021-11-29 | Ptc Therapeutics Inc | 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére |
| AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| MX2007015422A (es) * | 2005-06-08 | 2008-02-21 | Novartis Ag | Oxadiazoles o isoxazoles policiclicos y su uso como ligandos del receptor de s1p. |
| WO2007132307A1 (en) * | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| WO2009043889A2 (en) * | 2007-10-04 | 2009-04-09 | Merck Serono S.A. | Oxadiazole derivatives |
| CN101815707B (zh) * | 2007-10-04 | 2015-09-02 | 默克雪兰诺有限公司 | 噁二唑二芳基化合物 |
-
2008
- 2008-12-17 US US12/809,816 patent/US8202856B2/en not_active Expired - Fee Related
- 2008-12-17 EA EA201070779A patent/EA020887B1/ru not_active IP Right Cessation
- 2008-12-17 WO PCT/EP2008/067776 patent/WO2009080663A1/en active Application Filing
- 2008-12-17 AU AU2008340113A patent/AU2008340113B2/en not_active Ceased
- 2008-12-17 BR BRPI0821357A patent/BRPI0821357A2/pt not_active IP Right Cessation
- 2008-12-17 CN CN200880125323.6A patent/CN101918395B/zh not_active Expired - Fee Related
- 2008-12-17 EP EP08864598.1A patent/EP2250165B1/en active Active
- 2008-12-17 MX MX2010007026A patent/MX2010007026A/es active IP Right Grant
- 2008-12-17 KR KR1020107016412A patent/KR20100110834A/ko not_active Application Discontinuation
- 2008-12-17 CA CA2710345A patent/CA2710345C/en not_active Expired - Fee Related
- 2008-12-17 JP JP2010538714A patent/JP5451633B2/ja not_active Expired - Fee Related
- 2008-12-19 AR ARP080105591A patent/AR070043A1/es not_active Application Discontinuation
-
2010
- 2010-06-21 IL IL206514A patent/IL206514A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL206514A (en) | 2013-09-30 |
| MX2010007026A (es) | 2010-10-05 |
| CN101918395B (zh) | 2014-04-16 |
| CN101918395A (zh) | 2010-12-15 |
| AU2008340113B2 (en) | 2014-01-09 |
| EA020887B1 (ru) | 2015-02-27 |
| US20100305092A1 (en) | 2010-12-02 |
| EA201070779A1 (ru) | 2011-02-28 |
| IL206514A0 (en) | 2010-12-30 |
| EP2250165A1 (en) | 2010-11-17 |
| KR20100110834A (ko) | 2010-10-13 |
| CA2710345A1 (en) | 2009-07-02 |
| JP5451633B2 (ja) | 2014-03-26 |
| JP2011506559A (ja) | 2011-03-03 |
| AU2008340113A1 (en) | 2009-07-02 |
| WO2009080663A1 (en) | 2009-07-02 |
| US8202856B2 (en) | 2012-06-19 |
| BRPI0821357A2 (pt) | 2017-05-23 |
| EP2250165B1 (en) | 2018-07-25 |
| CA2710345C (en) | 2016-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070043A1 (es) | Derivados de triazol oxadiazoles; una composicion farmaceutica en base al compuesto; uso de los compuestos para preparar medicamentos y proceso de preparacion de dichos compuestos | |
| ES2607952T3 (es) | Derivados tricíclicos de Pirazol Amina | |
| AR076183A1 (es) | Derivados heterociclicos inhibidores de dihidroorotato deshidrogenasa, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento del cancer y otros trastornos autoinmunes. | |
| AR068730A1 (es) | Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen,proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas. | |
| AR084507A1 (es) | Derivados de indazoliltriazol | |
| AR068731A1 (es) | Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas. | |
| AR067877A1 (es) | Compuestos de pirimidina | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR060591A1 (es) | Compuestos imidazo | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR076187A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen | |
| ES2589558T3 (es) | Derivados de pirimidin pirazolilo | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR087549A1 (es) | Derivados de 5-fluor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona | |
| AR075475A1 (es) | Derivados heterociclicos de piperazina utiles como agentes herbicidas y proceso para combatir el crecimiento de plantas indeseadas. | |
| SV2007002397A (es) | Aminopiridinas como inhibidores de b-secretasa ref. am101663 | |
| AR057023A1 (es) | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa | |
| CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
| AR059087A1 (es) | Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas. | |
| AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
| AR072148A1 (es) | Derivados de quinoxalindiona | |
| AR072586A1 (es) | Derivados de sulfamidas sustituidas, procesos para su preparacion y su uso para el tratamiento de trastornos del sistema nervioso y del metabolismo. | |
| EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
| ES2572137T3 (es) | Procedimiento para la síntesis de mandipropamida y derivados de la misma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |